Haleon (NYSE:HLN) Issues Quarterly Earnings Results

Haleon (NYSE:HLN) posted its quarterly earnings data on Thursday. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01), Zacks reports. The business had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. Haleon had a return on equity of 19.85% and a net margin of 9.71%. During the same quarter in the prior year, the company earned $0.08 earnings per share.

Haleon Stock Performance

NYSE:HLN traded up $0.30 on Friday, hitting $9.63. The company’s stock had a trading volume of 6,995,874 shares, compared to its average volume of 4,408,089. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53. Haleon has a one year low of $7.70 and a one year high of $9.73. The stock has a fifty day moving average of $8.65 and a two-hundred day moving average of $8.43. The firm has a market capitalization of $43.97 billion, a P/E ratio of 32.10, a price-to-earnings-growth ratio of 2.69 and a beta of 0.24.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Thursday, September 19th. Shareholders of record on Friday, August 16th will be given a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon’s dividend payout ratio (DPR) is presently 70.00%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HLN. HSBC assumed coverage on Haleon in a research report on Wednesday, April 17th. They set a “buy” rating for the company. Berenberg Bank assumed coverage on shares of Haleon in a research note on Wednesday, June 5th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.